Clinical research partner dMed has completed a series B round that included returning investor Lilly Asia Ventures as it seeks to expand internationally.

China-based clinical research provider dMed Biopharmaceutical recently closed a $50m series B round featuring Lilly Asia Ventures, an investment vehicle overseen by pharmaceutical firm Eli Lilly, it announced on Wednesday. Healthcare investment firm Vivo Capital led the round, which included Legend Capital, the venture capital firm formed by conglomerate Legend Holdings, and fellow VC firm…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.